Synthetics Biologics Stock News

Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) Interim blinded safety and phar

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer Houman Ashrafian

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China

Synthetic Biologics, Inc. (NYSE:SYN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief

Synthetic Biologics, Inc. (NYSE:SYN ) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Informati

Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2021 Results - Earnings Call Transcript

Synthetic Biologics (NYSE:SYN) is scheduled to announce FY earnings results on Wednesday, March 16th, after market close.The consensus EPS Estimate is -$0.10 (+84.8% Y/Y) and the…

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) with the stream of -1.83% also noticed, India Synthetic Biologics, Inc. (AMEX:SYN) encountered a rapid change of -4.77% in the last hour of Friday’s trading session. … The post Top-notch Stock: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Synthetic Biologics, Inc. (AMEX:SYN) appeared first on Stocks Equity .

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of h

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) with the stream of -2.44% also noticed, India Synthetic Biologics, Inc. (AMEX:SYN) encountered a rapid change of 0.21% in the last hour of Monday’s trading session. … The post Stock on fire: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Synthetic Biologics, Inc. (AMEX:SYN) appeared first on Stocks Equity .

NEW YORK, United States, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled "Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and By Regions Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 2026" in its research database. "According to the latest research study, the demand of global Irritable Bowel Syndrome (IBS) Diagnostics Market size & share was valued at approximately USD 1.2 Billion in 2020 and is expected to reach a value of around USD 2.3 Billion by 2026, at a compound annual growth rate (CAGR) of about 9.7% during the forecast period 2021 to 2026." What is Irritable Bowel Syndrome (IBS) Diagnostics? How big is the Irritable Bowel Syndrome (IBS) Diagnostics Market? Market Overview & Coverage: Irritable bowel syndrome is a medical condition that pertains to irregular bowel movement and is accompanied by extreme pain in the stomach followed by diarrhoea, cramping, and constipation among others.

ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high

Synthetic Biologics (SYN) said VCN Biosciences'' VCN-01 received the U.S